Dr. Lal PathLabs Limited has announced that its Board of Directors will meet on January 30, 2026, to consider and approve the company's unaudited financial results for the third quarter of fiscal year 2026. The meeting will address both standalone and consolidated financial results for the quarter and nine months ending December 31, 2025. Additionally, the company will host an earnings conference call on the same day to discuss the financial and operating performance with investors and analysts.

Board Meeting Details

The healthcare company has scheduled the board meeting in accordance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting will specifically focus on reviewing and approving the unaudited financial performance for the specified period.

Earnings Conference Call

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, Dr. Lal PathLabs will host an earnings conference call for investors and analysts on Friday, January 30, 2026, at 4:00 PM IST. The call will discuss the financial and operating performance for Q3 & 9M FY26.

The conference call will begin with a brief discussion by management on Q3 & 9M FY26 financial and operating performance, followed by a question-and-answer session for participants.

Trading Window Closure

In compliance with regulatory requirements, Dr. Lal PathLabs has announced the closure of its trading window for company securities. This measure aligns with the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal Code for Prevention of Insider Trading.

Company Overview

Dr. Lal PathLabs Limited is one of India's leading consumer healthcare brands in diagnostic services with an integrated nationwide network. The company offers a broad range of diagnostic and related healthcare tests and services, with a catalogue including 385 test panels, 3,172 pathology tests and 1,455 radiology and cardiology tests. The company operates 298 clinical labs, 6,607 Patient Service Centers and 12,365 Pick-up Points, processing approximately 86 million samples from 28.8 million patients.

Dr. Lal Path Labs Limited has executed a Fifth Supplementary Trust Deed to amend its Employee Welfare Trust, incorporating the newly approved Restricted Stock Unit Plan 2025. The amendment was completed on December 9, 2025, and registered with the Sub-Registrar of Assurances in New Delhi on December 10, 2025.

New RSU Plan Integration

The trust deed amendment follows the shareholders' approval of the Dr. Lal PathLabs Employee Restricted Stock Unit Plan 2025 (RSU 2025) through a special resolution passed on December 7, 2025. The modification ensures compliance with SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

Trust Structure and Trustees

The Employee Welfare Trust operates under three designated trustees who will oversee the implementation of the new RSU plan:

• Mr. Munender Soperna: Group Chief Information & Digital Officer, aged 51 years
• Dr. Reena Nakra: Principal Director, Lab Management Technical Excellence, aged 53 years
• Mr. Manoj Kumar Garg: Group Chief Human Resources Officer, aged 57 years

Expanded Employee Benefit Plans

The amended trust deed now encompasses a comprehensive range of employee benefit schemes under the expanded definition of "Plan":

• Dr. Lal PathLabs Employee Stock Option Plan 2010 (ESOP 2010)
• Dr. Lal PathLabs Employee Share Purchase Scheme 2015 (ESPS 2015)
• Dr. Lal PathLabs Employee Restricted Stock Unit 2016 (RSU 2016)
• Dr. Lal PathLabs Employee Stock Option Plan 2022 (ESOP 2022)
• Dr. Lal PathLabs Employee Restricted Stock Unit Plan 2025 (RSU 2025)
• Any future employee benefit plans with provisions for modifications

Trust Evolution Timeline

The Employee Welfare Trust has undergone multiple amendments since its establishment:

Regulatory Compliance

The Fifth Supplementary Trust Deed maintains continuity with all previous amendments while specifically addressing the requirements of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The document establishes that in case of conflicts between different versions, the provisions of the Fifth Supplementary Trust Deed will prevail for matters specifically addressed therein.

The trust deed amendment represents Dr. Lal PathLabs' continued commitment to employee welfare through structured equity participation programs, ensuring regulatory compliance while expanding benefit options for eligible employees.